IONIS PHARMACEUTICALS INC. news, videos and press releases
For more news please use our advanced search feature.
IONIS PHARMACEUTICALS INC. - More news...
IONIS PHARMACEUTICALS INC. - More news...
- Ionis to host expert panel discussion on sHTG
- Ionis to present at upcoming investor conferences
- Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
- Ionis and Ono announce global license agreement for sapablursen in polycythemia vera
- WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
- Ionis to present at upcoming investor conferences
- New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control
- Ionis reports fourth quarter and full year 2024 financial results
- Ionis to hold fourth quarter and full year 2024 financial results webcast
- Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum
- Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference
- TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet
- Ionis to present at upcoming investor conferences
- Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome
- Ionis reports third quarter 2024 financial results
- Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE
- Ionis to hold third quarter 2024 financial results webcast
- WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis
- New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
- Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease
- Ionis announces pricing of $500.3 million public offering
- Ionis announces proposed public offering of common stock
- Ionis to present at upcoming investor conferences
- Ionis reports second quarter 2024 financial results
- Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome
- Ionis to hold second quarter 2024 financial results webcast
- Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease
- Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome
- Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed
- Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema
